GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 With a 33.2% CAGR | MarketsandMarkets
GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 With a 33.2% CAGR | MarketsandMarkets
CHICAGO, July 11, 2024 /PRNewswire/ -- The global GLP-1 analogues market is poised for substantial growth, projected to expand from USD 47.4 billion in 2024 to USD 471.1 billion by 2032, at a robust CAGR of 33.2%. Key drivers include the drugs' efficacy in managing diabetes and obesity, driving high demand and clinical research advancements. The market is dominated by two major players, Novo Nordisk A/S and Eli Lilly and Company, creating significant entry barriers. Opportunities lie in expanding therapeutic applications beyond diabetes to include conditions like NASH and Alzheimer's disease. However, challenges such as patient non-adherence and the dominance of injectable formats hinder market growth. North America leads in market share, supported by accessibility and demand for GLP-1 analogues. Key players like Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca are pivotal in shaping market dynamics through extensive R&D and strategic expansions.
全球GLP-1类似物市场将迎来可观的增长，预计从2024年的474亿美元扩展到2032年的4711亿美元，CAGR高达33.2％。关键驱动因素包括这些药物在管理糖尿病和肥胖症方面的功效，推动了高需求和临床研究的进展。市场由Novo Nordisk A/S和Eli Lilly and Company两家主要公司主导，创造了重要的进入壁垒。机遇在于将治疗应用扩展到糖尿病以外的其他病症，如NASH和阿尔茨海默氏病。然而，患者不遵从和注射剂的主导地位等挑战阻碍了市场增长。北美市场份额领先，得到了GLP-1类似物的易得性和需求的支持。Novo Nordisk，Eli Lilly，赛诺菲安万特和阿斯利康等关键企业通过广泛的研发和战略扩张对塑造市场动态起着关键作用。